Inhibition of miR-146b expression increases radioiodine-sensitivity in poorly differential thyroid carcinoma via positively regulating NIS expression

Li, Luchuan; Lv, Bin; Chen, Bo; Guan, Ming; Sun, Yonghai; Li, Haipeng; Zhang, Bin-Bin; Ding, Changyuan; He, Shan; Zeng, Qingdong

doi:10.1016/j.bbrc.2015.04.134

Cited by 39 publications

(35 citation statements)

References 26 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MiR-146b specifically represses PAX8 and NIS, two genes essential for determining the differentiate phenotype of thyroid cancer (40). Antagonizing miR-146b in human thyroid cancer cells has been shown to reinduce NIS-mediated iodide uptake (41). Apart from NIS, miR-146b is predicted to repress other iodide-metabolizing proteins such as DEHAL and DIO2 (40).…”

Section: From Cancer Genes To Signaling and Differentiation: Toward Amentioning

confidence: 99%

ENDOCRINE TUMOURS: Advances in the molecular pathogenesis of thyroid cancer: lessons from the cancer genome

Riesco‐Eizaguirre

Santisteban

2016

European Journal of Endocrinology

View full text Add to dashboard Cite

Thyroid cancer is the most common endocrine malignancy giving rise to one of the most indolent solid cancers, but also one of the most lethal. In recent years, systematic studies of the cancer genome, most importantly those derived from The Cancer Genome Altas (TCGA), have catalogued aberrations in the DNA, chromatin, and RNA of the genomes of thousands of tumors relative to matched normal cellular genomes and have analyzed their epigenetic and protein consequences. Cancer genomics is therefore providing new information on cancer development and behavior, as well as new insights into genetic alterations and molecular pathways. From this genomic perspective, we will review the main advances concerning some essential aspects of the molecular pathogenesis of thyroid cancer such as mutational mechanisms, new cancer genes implicated in tumor initiation and progression, the role of non-coding RNA, and the advent of new susceptibility genes in thyroid cancer predisposition. This look across these genomic and cellular alterations results in the reshaping of the multistep development of thyroid tumors and offers new tools and opportunities for further research and clinical development of novel treatment strategies.

show abstract

Section: From Cancer Genes To Signaling and Differentiation: Toward Amentioning

confidence: 99%

ENDOCRINE TUMOURS: Advances in the molecular pathogenesis of thyroid cancer: lessons from the cancer genome

Riesco‐Eizaguirre

Santisteban

2016

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Many patients with advanced thyroid cancer do not benefit from the radioiodine therapy due to the reduced expression and function of the Na C /I -symporter (NIS). It was shown that lowered levels of NIS in thyroid tumors are at least in part caused by the overexpression of miR-339 and miR-146b, and inhibition of these microRNAs results in the increased uptake of radioactive iodine by the thyroid cancer cells (68,69,70). Data obtained in the in vitro experiments provided the basis for a number of preclinical studies related to the modulation of microRNAs in PTC, currently performed mainly on mouse models.…”

Section: The Potential Of Micrornas In Thyroid Cancer Treatmentmentioning

confidence: 99%

MECHANISMS IN ENDOCRINOLOGY: MicroRNA in diagnostics and therapy of thyroid cancer

Wójcicka

Kolanowska

Jażdżewski

2016

European Journal of Endocrinology

View full text Add to dashboard Cite

MicroRNAs, short non-coding regulators of the gene expression, are subjects of numerous investigations assessing their potential use in the diagnostics and management of human diseases. In this review, we focus on studies that analyze the utility of microRNAs as novel diagnostic and therapeutic tools in follicular cell-derived thyroid carcinomas. This very interesting and promising field brings new insight into future strategies for personalized medicine.

show abstract

“…MiR-146b reveals aggressive features, not only in thyroid papillary cancer but also in other malignancies [56]. Therapeutic inhibition of miR-146b in dedifferentiated thyroid carcinoma represents a promising way to enhance radioiodine uptake and the efficacy of radioactive therapy [57]. However, Sondermann et al [59] found no significant differences in miR-146b expression between recurrent and nonrecurrent papillary carcinomas.…”

Section: Prognostic Mirsmentioning

confidence: 99%

“…However, only sporadic studies have so far focused on the association between miR deregulation and thyroid cancer prognosis and therapy [40,55,56,57,58,59]. …”

Section: Prognostic Mirsmentioning

confidence: 99%

Pathobiology of MicroRNAs and Their Emerging Role in Thyroid Fine-Needle Aspiration

2015

View full text Add to dashboard Cite

Objective: MicroRNAs (miRs) are noncoding, single-stranded regulatory RNA molecules involved in the posttranscriptional regulation of gene expression. They control the development and maintenance of the diverse cellular processes including proliferation, differentiation, motility and apoptosis. Expression of miRs is tissue-specific and each alteration of the tissue miR profile is associated with a distinct disease status. Study Design: We reviewed the literature on the expression of miRs in thyroid tumors, focusing on methodology and diagnostic and prognostic output. Separately, we analyzed 11 studies on miR profiles in thyroid cytological material. Results: Numerous studies have evaluated the miR profiles of thyroid tumors in an attempt to find a possible diagnostic and prognostic role. Both downregulation and upregulation of numerous miRs was found, but differences between the surgical pathology specimens and corresponding fine-needle aspirates in the expression of the same miRs were also reported. Conclusions: The results from surgically resected material cannot be extrapolated into preoperative use without validation. For diagnostic use, the strong overlap between follicular adenoma and follicular carcinoma miR profiles is challenging. In summary, miR-221 and miR-222 are consistently upregulated in different types of thyroid carcinomas and might be used as markers of malignancy.

show abstract

Inhibition of miR-146b expression increases radioiodine-sensitivity in poorly differential thyroid carcinoma via positively regulating NIS expression

Cited by 39 publications

References 26 publications

ENDOCRINE TUMOURS: Advances in the molecular pathogenesis of thyroid cancer: lessons from the cancer genome

ENDOCRINE TUMOURS: Advances in the molecular pathogenesis of thyroid cancer: lessons from the cancer genome

MECHANISMS IN ENDOCRINOLOGY: MicroRNA in diagnostics and therapy of thyroid cancer

Pathobiology of MicroRNAs and Their Emerging Role in Thyroid Fine-Needle Aspiration

Contact Info

Product

Resources

About